Kroemer, Heyo Klaus

[["dc.bibliographiccitation.firstpage","8"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Pharmacogenetics and genomics"],["dc.bibliographiccitation.lastpage","18"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Meyer zu Schwabedissen, Henriette E."],["dc.contributor.author","Albers, Martin"],["dc.contributor.author","Baumeister, Sebastian E."],["dc.contributor.author","Rimmbach, Christian"],["dc.contributor.author","Nauck, Matthias"],["dc.contributor.author","Wallaschofski, Henri"],["dc.contributor.author","Siegmund, Werner"],["dc.contributor.author","Völzke, Henry"],["dc.contributor.author","Kroemer, Heyo K."],["dc.date.accessioned","2018-08-20T13:02:42Z"],["dc.date.available","2018-08-20T13:02:42Z"],["dc.date.issued","2015"],["dc.description.abstract","BACKGROUND: The efficacy of statins, which are used commonly in primary and secondary prevention of cardiovascular diseases, shows a wide range of interindividual variability. Genetic variants of OATP1B1, a hepatic uptake transporter, can modify access of statins to its therapeutic target, thereby potentially altering drug efficacy. We studied the impact of genetic variants of OATP1B1 on the lipid-lowering efficacy of statins in a population-based setting. MATERIALS AND METHODS: The basis of the analysis was the Study of Health in Pomerania, a cohort of 2732 men and women aged 20-81 years. Included in the statistical analysis to evaluate the impact of OATP1B1 on therapeutic efficacy of statins were 214 individuals diagnosed with dyslipidaemia during initial recruitment and receiving statins during the 5-year follow-up. RESULTS: Analysing the impact of the OATP1B1 genotype, we observed a trend for lower statin-induced total cholesterol reduction in carriers of the SLCO1B1 512C variant. Restricting the analysis to patients receiving simvastatin, pravastatin, lovastatin and fluvastatin indicated a statistically significant association of the OATP1B1 genotype on lipid parameters at the 5-year follow-up. No such effect was observed for atorvastatin. Calculation of achievement of treatment goals according to the NCEP-ATPIII guidelines showed a lower rate of successful treatment when harbouring the mutant allele for patients taking simvastatin (46.7 vs. 73.9%). A similar trend was observed for pravastatin (34.4 vs. 70.4%). CONCLUSION: Genetic variants of OATP1B1 leading to impaired hepatic uptake of statins translated into reduced drug efficacy in a population-based cohort."],["dc.identifier.doi","10.1097/FPC.0000000000000098"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15443"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1744-6872"],["dc.title","Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1405"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Metabolomics"],["dc.bibliographiccitation.lastpage","1415"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Friedrich, Nele"],["dc.contributor.author","Budde, Kathrin"],["dc.contributor.author","Suhre, Karsten"],["dc.contributor.author","Voelker, Uwe"],["dc.contributor.author","John, Ulrich"],["dc.contributor.author","Felix, Stephan B."],["dc.contributor.author","Kroemer, Heyo K."],["dc.contributor.author","Grabe, Hans Joergen"],["dc.contributor.author","Voelzke, Henry"],["dc.contributor.author","Nauck, Matthias"],["dc.contributor.author","Wallaschofski, Henri"],["dc.date.accessioned","2018-11-07T09:51:23Z"],["dc.date.available","2018-11-07T09:51:23Z"],["dc.date.issued","2015"],["dc.description.abstract","Recently research provides evidence that blood metabolite profiles predicted type 2 diabetes. We aimed to assess the relation of urine metabolites measured via nuclear magnetic resonance spectroscopy with incident type 2 diabetes in a sample of 1353 men and 1356 women. Within 5 years, 87 men and 50 women developed diabetes. Five and 16 urine metabolites were associated with incident diabetes in men and women, respectively. Only three of these metabolites (glucose, lactate and glycine) were found in both sexes. In women, e.g. acetate, carnitine, N,N-dimethylglycine, trigonelline, 3-hydroxyisovalerate, alanine, formate, glycolate, trimethylamine N-oxide and tau-methylhistidine were positively related with diabetes. Receiver operating characteristic (ROC) analysis revealed that compared with a standard model, a model additionally adjusted for urine glucose, trigonelline and trimethylamine N-oxide levels showed a better discrimination between incident diabetes cases and non-cases in women (AUC = 0.874 and 0.903, p = 0.019). In men, valine and 4-hydroxyphenylacetate were found as markers of diabetes. However, ROC analysis did not reveal any improvement in discrimination based on urine metabolites. In conclusion, we confirmed the potential of metabolomics to assess the risk of type 2 diabetes and detected pronounced sex differences. Moreover, we demonstrated the practicability of spot urine samples as potential non-invasive diabetes screening approach."],["dc.identifier.doi","10.1007/s11306-015-0795-6"],["dc.identifier.isi","000360715300034"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35903"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1573-3890"],["dc.relation.issn","1573-3882"],["dc.title","Sex differences in urine metabolites related with risk of diabetes using NMR spectroscopy: results of the study of health in pomerania"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e96875"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PLOS ONE"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Schwedhelm, Edzard"],["dc.contributor.author","Wallaschofski, Henri"],["dc.contributor.author","Atzler, Dorothee"],["dc.contributor.author","Dörr, Marcus"],["dc.contributor.author","Nauck, Matthias"],["dc.contributor.author","Volker, Uwe"],["dc.contributor.author","Kroemer, Heyo K."],["dc.contributor.author","Volzke, Henry"],["dc.contributor.author","Böger, Rainer H."],["dc.contributor.author","Friedrich, Nele"],["dc.date.accessioned","2018-08-15T06:50:42Z"],["dc.date.available","2018-08-15T06:50:42Z"],["dc.date.issued","2014"],["dc.description.abstract","BACKGROUND: L-Arginine and its dimethylated derivatives asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) have been associated with cardiovascular (CV) and all-cause mortality in populations at risk. The present study aimed to investigate the prognostic value of L-arginine and its derivatives in the general population. METHODS AND RESULTS: We evaluated 3,952 individuals (1,936 men and 2,016 women) aged 20-81 (median (IQR) 51 (37; 64) years) from the population-based Study of Health in Pomerania (SHIP). Associations of continuous [per standard deviation (SD) increase] and categorized (age- and sex-specific tertiles) serum L-arginine, ADMA, and SDMA concentrations with all-cause and cause-specific mortality were analysed. During a median (IQR) follow-up period of 10.1 (9.3; 10.8) years (38,476 person-years), 426 deaths (10.8%) were observed, including 139 CV deaths (3.5%), and 150 cancer deaths (3.8%). After multivariable adjustment, we revealed a positive association of SDMA with all-cause [hazard ratio (HR) per SD increase: 1.16, 95% confidence interval (CI): 1.07-1.25] and CV mortality [HR: 1.19, 95% CI: 1.05-1.35]. In contrast, we did not observe any association of SDMA with cancer mortality. Neither L-arginine nor ADMA were associated with all-cause or CV mortality. CONCLUSION: SDMA, but not ADMA, is an independent predictor of all-cause and CV mortality in a large population-based cohort of European ancestry."],["dc.identifier.doi","10.1371/journal.pone.0096875"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10120"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15305"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.relation.eissn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Incidence of all-cause and cardiovascular mortality predicted by symmetric dimethylarginine in the population-based study of health in pomerania"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","144"],["dc.bibliographiccitation.journal","Journal of Translational Medicine"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Grabe, Hans Joergen"],["dc.contributor.author","Assel, Heinrich"],["dc.contributor.author","Bahls, Thomas"],["dc.contributor.author","Doerr, Marcus"],["dc.contributor.author","Endlich, Karlhans"],["dc.contributor.author","Endlich, Nicole"],["dc.contributor.author","Erdmann, Pia"],["dc.contributor.author","Ewert, Ralf"],["dc.contributor.author","Felix, Stephan B."],["dc.contributor.author","Fiene, Beate"],["dc.contributor.author","Fischer, Tobias"],["dc.contributor.author","Flessa, Steffen"],["dc.contributor.author","Friedrich, Nele"],["dc.contributor.author","Gadebusch-Bondio, Mariacarla"],["dc.contributor.author","Salazar, Manuela Gesell"],["dc.contributor.author","Hammer, Elke"],["dc.contributor.author","Haring, Robin"],["dc.contributor.author","Havemann, Christoph"],["dc.contributor.author","Hecker, Michael"],["dc.contributor.author","Hoffmann, Wolfgang"],["dc.contributor.author","Holtfreter, Birte"],["dc.contributor.author","Kacprowski, Tim"],["dc.contributor.author","Klein, Kathleen"],["dc.contributor.author","Kocher, Thomas"],["dc.contributor.author","Kock, Holger"],["dc.contributor.author","Krafczyk, Janina"],["dc.contributor.author","Kuhn, Jana"],["dc.contributor.author","Langanke, Martin"],["dc.contributor.author","Lendeckel, Uwe"],["dc.contributor.author","Lerch, Markus M."],["dc.contributor.author","Lieb, Wolfgang"],["dc.contributor.author","Lorbeer, Roberto"],["dc.contributor.author","Mayerle, Julia"],["dc.contributor.author","Meissner, Konrad"],["dc.contributor.author","Schwabedissen, Henriette E. Meyer zu"],["dc.contributor.author","Nauck, Matthias"],["dc.contributor.author","Ott, Konrad"],["dc.contributor.author","Rathmann, Wolfgang"],["dc.contributor.author","Rettig, Rainer"],["dc.contributor.author","Richardt, Claudia"],["dc.contributor.author","Salje, Karen"],["dc.contributor.author","Schminke, Ulf"],["dc.contributor.author","Schulz, Andrea"],["dc.contributor.author","Schwab, Matthias"],["dc.contributor.author","Siegmund, Werner"],["dc.contributor.author","Stracke, Sylvia"],["dc.contributor.author","Suhre, Karsten"],["dc.contributor.author","Ueffing, Marius"],["dc.contributor.author","Ungerer, Saskia"],["dc.contributor.author","Voelker, Uwe"],["dc.contributor.author","Voelzke, Henry"],["dc.contributor.author","Wallaschofski, Henri"],["dc.contributor.author","Werner, Vivian"],["dc.contributor.author","Zygmunt, Marek T."],["dc.contributor.author","Kroemer, Heyo K."],["dc.date.accessioned","2018-11-07T09:39:59Z"],["dc.date.available","2018-11-07T09:39:59Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Individualized Medicine aims at providing optimal treatment for an individual patient at a given time based on his specific genetic and molecular characteristics. This requires excellent clinical stratification of patients as well as the availability of genomic data and biomarkers as prerequisites for the development of novel diagnostic tools and therapeutic strategies. The University Medicine Greifswald, Germany, has launched the \"Greifswald Approach to Individualized Medicine\" (GANI_MED) project to address major challenges of Individualized Medicine. Herein, we describe the implementation of the scientific and clinical infrastructure that allows future translation of findings relevant to Individualized Medicine into clinical practice. Methods/design: Clinical patient cohorts (N > 5,000) with an emphasis on metabolic and cardiovascular diseases are being established following a standardized protocol for the assessment of medical history, laboratory biomarkers, and the collection of various biosamples for bio-banking purposes. A multi-omics based biomarker assessment including genome-wide genotyping, transcriptome, metabolome, and proteome analyses complements the multi-level approach of GANI_MED. Comparisons with the general background population as characterized by our Study of Health in Pomerania (SHIP) are performed. A central data management structure has been implemented to capture and integrate all relevant clinical data for research purposes. Ethical research projects on informed consent procedures, reporting of incidental findings, and economic evaluations were launched in parallel."],["dc.identifier.doi","10.1186/1479-5876-12-144"],["dc.identifier.isi","000338469800002"],["dc.identifier.pmid","24886498"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10153"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33415"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1479-5876"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Cohort profile: Greifswald approach to individualized medicine (GANI_MED)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]